Kiniksa (KNSA) CFO Mark Ragosa Exercises Options, Withholds Shares

What Happened
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals (KNSA), exercised option-derived/convertible derivatives totaling 9,104 underlying shares on September 1, 2026. To cover tax withholding and exercise-related obligations, 4,404 shares were surrendered/withheld at $79.28 per share for a total of $349,149. At the same time he was granted/awarded 38,950 restricted share units (RSUs) in two awards (7,800 and 31,150 RSUs) that vest over time.

Key Details

• Transaction date: September 1, 2026; Form 4 filed September 3, 2026 (appears timely).
• Exercise/convert (M): 2,694 + 1,750 + 1,591 + 3,069 = 9,104 shares exercised.
• Tax/payment withholding (F): 4,404 shares surrendered at $79.28 = $349,149.
• Grants (A): 7,800 RSUs and 31,150 RSUs awarded (total 38,950 RSUs) at $0.00 (contingent units).
• Some exercised/share-conversion line items list $0.00 disposals — these reflect derivative-to-share settlements or netting/withholding, not an open-market sale.
• Shares owned after transaction: Not reported on this Form 4.
• Footnotes: RSUs represent a right to one Class A ordinary share (F1). RSU awards vest over four years with 25% annual vesting (F2, F4–F7). The option vesting schedule begins Sept 1, 2026 with 25% at year one and monthly vesting thereafter (F3).
• Transaction codes: M = option exercise/conversion, F = payment of exercise price/tax withholding, A = grant/award.

Context
This appears to be a routine cashless/net exercise and incentive-award activity: Ragosa exercised vested derivative awards and had a portion of the resulting shares withheld to satisfy tax liabilities rather than selling shares on the open market. The RSU grants are time-based awards that vest in future installments and do not represent immediate market purchases or sales. These actions are administrative/compensation-related and not necessarily a directional signal about the insider’s view of the stock.